ArticleHuman vaccines & immunotherapeutics2025
Herpes zoster vaccination and vaccine preferences among persons aged 50-64 years in Australia: Findings from a discrete choice experiment.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccine-preventable herpes zoster (HZ) poses substantial burden among Australian adults ≥50 years of age (YOA) despite available vaccination. This study aimed to understand the HZ vaccine-related preferences of adults paying out-of-pocket for HZ vaccination, to facilitate targeted recommendations by physicians and ultimately reduce disease burden. A discrete choice experiment was conducted (March-May 2023) to quantify preferences for HZ vaccine attributes among adults 50-64 YOA: HZ-naïve with selected self-reported comorbidities (n = 525; each comorbidity: n = 75), HZ-naïve without comorbidities (n = 150), and current/former HZ patients (n = 150). Each choice task comprised a "no vaccine" option and three hypothetical HZ vaccine profiles characterized by five attributes with varying levels. Attributes and levels were identified through literature review/concept elicitation/cognitive interviews/expert opinion. The attributes that most influenced HZ vaccine choice (measured by relative importance [RI]) were recommendation by government guidelines/medical societies, then HZ lifetime risk reduction, and protection duration. HZ-naïve adults with comorbidities indicated lower RI of recommendation by government guidelines/medical societies and higher RI of HZ lifetime risk reduction than other respondents. Between HZ-naïve adults without comorbidities and HZ patients, there were no significant differences in RI of each attribute. Respondents with comorbidities, whether overall or grouped by comorbidity, shared identical top three attributes. Between HZ-naïve, HZ-vaccinated adults (n = 146) and those without vaccination (n = 529), each top three attribute (recommendation by government guidelines/medical societies, HZ lifetime risk reduction, and protection duration) showed significantly different RI (p <.001). Findings elucidate the motivations underlying HZ vaccine preferences among Australian adults 50-64 YOA, guiding physician-patient conversations about HZ vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.